Paradox Immunotherapeutics Inc.

Paradox Immunotherapeutics Inc. is dedicated to developing advanced monoclonal antibody treatments targeting protein misfolding diseases, aiming to provide innovative solutions for conditions like ALS and Alzheimer’s. Founded in 2019 and based in Toronto, Canada, Paradox Immunotherapeutics specializes in monoclonal antibodies for neurodegenerative disorders. The company has engaged in one major funding round, raising a total of USD 10.

00 mn. Its most recent deal occurred on February 25, 2025, led by SymBiosis Capital Management, which will support further development of their antibody therapies. Paradox Immunotherapeutics specializes in the development of monoclonal antibody (mAb) treatments aimed at addressing protein misfolding diseases. Their core product offerings focus on creating specialized antibodies that selectively target misfolded proteins responsible for diseases such as ALS, Alzheimer’s, and Parkinson’s, while preserving healthy proteins.

This targeted approach is designed to mitigate the effects of these diseases, presenting a potentially transformative solution for patients suffering from conditions that are currently considered difficult to manage or incurable. Paradox's products are primarily aimed at healthcare providers and institutions engaged in the treatment of neurodegenerative diseases, with an emphasis on markets in North America, Europe, and parts of Asia, where there is a significant prevalence of the aforementioned diseases. The revenue generation model for Paradox Immunotherapeutics is structured around partnerships and collaborations with pharmaceutical companies and healthcare providers. These partnerships involve licensing agreements for the use of Paradox’s proprietary antibody technologies in clinical settings, as well as direct sales to healthcare institutions following successful clinical trials.

Revenue is anticipated through milestone payments during the development phases and royalties based on product sales once they reach the market. Paradox's focus on innovative therapies for protein misfolding diseases positions it within a competitive biotech landscape, catering to a market that demands cutting-edge treatments for serious medical conditions. In February 2025, Paradox Immunotherapeutics Inc. raised USD 10.

00 mn in venture funding from SymBiosis Capital Management. This funding will be utilized to advance the development of antibody therapies targeting protein misfolding diseases. Plans include launching new products aimed at treating these conditions and expanding into markets across North America, Europe, and parts of Asia by the end of 2025.